Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.26% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.26%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.73%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.61%.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.73%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.26% 10-Q · filed 2026-08-19 | |||
| 2022-12-31 | 1.73% 10-K/A · filed 2024-05-14 | |||
| 2022-09-30 | 1.73% 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 1.73% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 1.73% 10-Q · filed 2022-05-13 | |||
| 2020-06-30 | 1.61% 10-Q · filed 2020-08-14 | |||
| 2020-03-31 | 1.61% 10-Q · filed 2020-06-18 | |||
| 2014-12-31 | 2.30% 8-K/A · filed 2016-07-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |